Abstract 24 Rodent-to-human transmission of hantaviruses is associated with severe disease. 25 Currently, no FDA-approved, specific antivirals or vaccines are available, and the requirement 26 for high biocontainment (BSL3) laboratories limits hantavirus research. To study hantavirus 27 entry in a BSL-2 laboratory, we set out to generate replication-competent, recombinant vesicular 28 stomatitis viruses (rVSVs) bearing the Gn/Gc entry glycoproteins. As previously reported, 29 rVSVs bearing New World hantavirus Gn/Gc were readily rescued from cDNAs, but their 30 counterparts bearing Gn/Gc from the Old World hantavirus, Hantaan virus (HTNV), were 31 refractory to rescue and only grew to low titers. However, serial passage of the rescued rVSV-32 HTNV Gn/Gc virus markedly increased its infectivity and capacity for cell-to-cell spread. This 33 gain in viral fitness was associated with the acquisition of two point mutations; I532K in the 34 cytoplasmic tail of Gn, and S1094L in the membrane-proximal stem of Gc. Follow-up 35 experiments with rVSVs and single-cycle VSV pseudotypes confirmed these results. 36 Mechanistic studies revealed that both mutations were determinative and contributed to viral 37 infectivity in a synergistic manner. Our findings indicate that the primary mode of action of these 38 mutations is to relocalize HTNV Gn/Gc from the Golgi complex to the cell surface, thereby 39 affording significantly enhanced Gn/Gc incorporation into budding VSV particles. Our results 40 suggest that enhancements in cell-surface expression of hantaviral glycoprotein(s) through 41 incorporation of cognate mutations could afford the generation of rVSVs that are otherwise 42 challenging to rescue. The robust replication-competent rVSV-HTNV Gn/Gc reported herein 43 may also have utility as a vaccine. 44 45 3 Importance 46 Human hantavirus infections cause pulmonary syndrome in the Americas and 47 hemorrhagic fever with renal syndrome (HFRS) in Eurasia. No FDA-approved vaccines and 48 therapeutics exist for these deadly viruses, and their development is limited by the requirement 49 for high biocontainment. In this study, we identified and characterized key amino acid changes in 50 the surface glycoproteins of HFRS-causing Hantaan virus that enhance their incorporation into 51 recombinant vesicular stomatitis virus (rVSV) particles. The replication-competent rVSV 52 genetically encoding Hantaan virus glycoproteins described in this work provides a powerful and 53 facile system to study hantavirus entry under lower biocontainment and may have utility as a 54 hantavirus vaccine.
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other bunyaviruses, are reported to bud into the Golgi apparatus. In keeping with these 154 observations, VSV G and HTNV Gn/Gc (Figs 3-4 ) localize primarily to the plasma membrane 155 and endoplasmic reticulum (ER)/Golgi apparatus, respectively (38) (39) (40) . We postulated that this 156 mismatch in the subcellular sites of viral budding and glycoprotein localization may account for 157 the poor growth of rVSV-HTNV Gn/Gc, and that the I532K/S1094L mutations might ameliorate 158 this mismatch. Accordingly, we examined the subcellular distribution of WT and mutant Gn and 159 Gc in transfected U2OS cells by immunofluorescence (IF) microscopy. Gn and Gc colocalization 160 was essentially complete for all variants (Fig. 3) , showing that the mutations do not alter relative 161 Gn and Gc distribution in cells. We further noted a predominantly perinuclear Gn/Gc staining for 162 all variants that colocalized with GM130, a marker for the Golgi apparatus ( Fig. 4) , indicating 163 that the mutants substantially retain Golgi localization. Interestingly, however, some cells 164 expressing the double mutant also displayed marked Gn/Gc staining in the cell periphery (yellow 165 arrows in Figs. 3 and 4) , suggesting that a subset of these molecules do localize to the plasma 166 membrane. 167 To directly examine this possibility, we immunostained U2OS cells transfected with 168 plasmids expressing WT or mutant Gn/Gc to visualize the cell surface expression of these 169 glycoproteins. The Gn mutation alone enhanced the cell-surface expression of both Gn and Gc, 170 whereas the Gc mutation alone had little or no effect. Interestingly, the double-mutant afforded 171 an even higher level of cell-surface Gn/Gc expression, indicating that the Gc mutation can act in 172 concert with its Gn counterpart to drive relocalization of Gn/Gc to the plasma membrane (Fig. 173 5A). Similar results were obtained with primary human umbilical vein endothelial cells 174 (HUVEC) transfected with HTNV Gn/Gc expression plasmids ( Fig. 5B) . Quantitation of cell-175 surface Gc expression in plasmid-transfected U2OS cells by flow cytometry (Fig. 5C) , and 293T 176 10 cells by on-cell ELISA (Fig. 5D) , further corroborated the synergistic enhancement of Gn/Gc 177 cell-surface expression conferred by the I532K and S1094L mutations. 
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Because VSV virions are known to acquire heterologous membrane proteins during viral 182 budding at the host-cell plasma membrane, we reasoned that enhanced cell-surface-expression of 183 mutant HTNV Gn/Gc might increase incorporation of the latter into VSV particles. To test this 184 hypothesis, we examined single-cycle VSV pseudotypes (pVSVs) bearing WT and mutant 185 Gn/Gc proteins for HTNV Gn/Gc incorporation by HTNV Gc-specific ELISA, after normalizing 186 viral particle content by VSV matrix protein M-specific immunoblotting (Fig. 6A) . Concordant 187 with their effects on the cell-surface expression level of each glycoprotein, the Gn mutation 188 alone enhanced incorporation of Gn/Gc into viral particles, whereas the Gc mutation did not, and 189 combination of both mutations afforded a further synergistic increase in Gn/Gc incorporation 190 ( Fig. 6B) . Taken together, these findings strongly suggest that relocalization of HTNV Gn/Gc 191 from the Golgi complex to the plasma membrane induced by the I532K/S1094L mutations 192 enhances rVSV-HTNV Gn/Gc infectivity by increasing viral glycoprotein incorporation into 193 virus particles. Gn/Gc. We hypothesized that I532K/S1094L mutations facilitate rVSV rescue by altering Gn/Gc 210 expression and/or localization. Both of these mutations alone or together did not significantly 211 affect total protein production ( Fig. 2) or colocalization of Gn and Gc (Fig. 3) . Although the 212 majority of the single or double mutant Gn/Gc proteins were still localized to the Golgi complex 213 ( Fig. 3) , as were the WT proteins, the Gn mutation alone (I532K) or together with the Gc 214 mutation (I532K/S1094L) showed significantly elevated cell-surface expression as seen by 215 immunofluorescence ( Figs. 3-4 , 5A-B), flow cytometry ( Fig. 5C ) and on-cell ELISA (Fig. 5C) . 216 As observed previously (16, 49), we also see some WT HTNV Gn/Gc protein expression on the 217 12 cell surface ( Figs. 3-5 ). However, the I532K/S1094L mutations consistently enhanced cell 218 surface expression, by 3-to 4-fold as compared to the WT, in multiple human cell lines (U2OS 219 and 293T), as well as primary cells (HUVECs), at multiple times post-transfection, suggesting 220 that this phenotype is not limited to a particular cell type or time point ( Figs. 3-5 ). Importantly, 221 enriched cell-surface expression correlated well with the levels of HTNV Gn/Gc incorporated in 222 the vesiculoviral pseudovirions ( Fig. 6) , strongly indicating that relocalization of Gn/Gc from 223 Golgi complex to the cell surface is the major mechanism by which these mutations enhance Belgrade virus (DOBV) carries isoleucine at position 532 (PUUV is an exception), but it is a 236 valine in that of the New World hantaviruses (Fig. 7) . Congruent with these differences in How does the I532K mutation enhance cell surface expression of HTNV Gn/Gc? I532 is 241 located in the region that has been shown to bind hantavirus nucleoprotein and RNA (58, 59), 242 just upstream of the dual zinc finger domains in the cytoplasmic tail of the Gn (Gn-CT) protein 243 ( Fig. 7) . Although Golgi retention of many bunyaviruses is mediated by Gn alone (60-65), Uukuniemi virus (UUKV), has also been suggested to be the Golgi retention signal for UUKV 250 Gn/Gc (52). We hypothesize that the I532K mutation relocalizes HTNV Gn/Gc to the cell 251 surface by disrupting its interaction with one or more unknown cellular factors that mediate 252 Golgi retention. The rVSV system described here could be useful for further studies required to 253 characterize this Golgi retention mechanism.
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How the Gc (S1094L) mutation increases rVSV-HTNV Gn/Gc infectivity is less clear. It 255 failed to enhance cell surface expression and VSV incorporation of Gn/Gc on its own (Figs. 3-5). 256 S1094 is highly conserved across hantaviruses and is located in the membrane-proximal, C-257 terminal half of the Gc stem (Fig. 7) . The Gc stem is critical for the formation of the postfusion 258 hairpin conformation (66) and peptides corresponding to its C-terminal half inhibit ANDV 259 infection and membrane fusion (67). Most of the Gc stem, including the S1094 residue was not 260 visualized in the hantavirus Gc crystal structure (68, 69) . Alteration in the physical curvature of 261 the membrane by the membrane-proximal region of the VSV glycoprotein stem region has been 262 proposed to enhance VSV budding efficiency (70). However, S1094L alone did not affect 263 14 budding efficiency (Fig. 1E, 6A) . We speculate that this mutation might also alter intersubunit 264 interactions and/or the glycoprotein fusogenicity. (VSV), carrying an eGFP gene, was described previously (36). HTNV Gn/Gc point mutations 287 (I532K, S1094L, or I532K/S1094L) were cloned into the genomic VSV (described above) and Immunofluorescence microscopy for HTNV Gn/Gc localization. Human U2OS osteosarcoma 318 cells plated on fibronectin-coated glass coverslips were transfected with 500 ng of empty vector 319 or HTNV Gn/Gc expression vectors together with 50 ng of eGFP expressing plasmid as 320 described above. At 24 h post-transfection, cells were fixed with 4% formaldehyde (Sigma) for 5 321 min and permeabilized with 0.1% Triton X-100 for 10 min at room temperature. After blocking,
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HTNV Gn and Gc were detected by incubating cells with an anti-HTNV Gn mouse mAb 3D5 323 (BEI Resources, 1:500 dilution) followed by anti-mouse AlexaFluor-488 antibody, or an anti-324 HTNV Gc human mAb 3G1 (4.6 µg/mL) followed by anti-human AlexaFluor-555 antibody 325 (Thermo Fisher), respectively. Anti-GM130 (1.25 µg/mL, BD Biosciences) was used to co-stain 326 Golgi apparatus. For surface staining, cells were placed on ice 10 min prior to blocking for 30 327 min at 4°C and incubated with the above-described HTNV Gn or Gc antibodies on ice before 328 fixing and staining with the secondary antibodies as above. Primary human umbilical vein 329 endothelial cells (HUVECs) were nucleofected with 4.75 µg of empty or HTNV Gn/Gc 330 expressing vectors, together with 50 ng eGFP, using the Amaxa Kit (program A-034, Lonza) 331 before staining for total Gn/Gc expression at 72 h post-nucleofection as described above for 332 U2OS cells. Coverslips were mounted on slides with Prolong containing DAPI (Thermo Fisher) 333 and were imaged using a Zeiss Axio Observer inverted microscope with 40x objective. 
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-CAA38922.1. WebLogoes were generated as described earlier (72).
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